Bruce Culleton
Chief Executive Officer ProKidney
Seminars
Wednesday 18th March 2026
Panel Discussion: How Can Novel Modalities be Used to Meet the Unmet Needs in CKD?
10:30 am
- Balancing innovation with clinical feasibility and scalable development in kidney disease
- Addressing AAV’s narrow tropism: how do we translate promise into real-world therapies?
- Exploring whether targeted delivery strategies must be disease-specific to maximize impact
- Ensuring RNAi and oligonucleotide therapies achieve durable, clinically meaningful kidney knockdown
Wednesday 18th March 2026
Advancing Cell Therapy in CKD: Integrating Mechanistic Insights and Clinical Evidence from Phase 2 and 3 Trials
2:00 pm
- Exploring the role of autologous cell therapy in treating advanced CKD, emphasizing its potential to preserve kidney function and delay the need for dialysis
- Presenting novel mechanistic studies that elucidate how specific renal cell populations in ProKidney’s REACT® therapy may stabilize and improve kidney function, potentially halting the progression of CKD
- Reviewing Phase 2 clinical trial results, including the REGEN-007 study, which demonstrated a statistically significant and clinically meaningful reduction in the annual decline of estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes and Stage 3b/4 CKD
- Discussing the strategic design of the Phase 3 PROACT 1 trial, incorporating learnings from Phase 2 to optimize patient outcomes and streamline the clinical development pathway
